RT Journal Article
SR Electronic
T1 SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.19.20248567
DO 10.1101/2020.12.19.20248567
A1 Tea, Fiona
A1 Stella, Alberto Ospina
A1 Aggarwal, Anupriya
A1 Darley, David Ross
A1 Pilli, Deepti
A1 Vitale, Daniele
A1 Merheb, Vera
A1 Lee, Fiona X. Z.
A1 Cunningham, Philip
A1 Walker, Gregory J.
A1 Brown, David A.
A1 Rawlinson, William D.
A1 Isaacs, Sonia R.
A1 Mathivanan, Vennila
A1 Hoffman, Markus
A1 Pöhlmann, Stefan
A1 Dwyer, Dominic E.
A1 Rockett, Rebeca
A1 Sintchenko, Vitali
A1 Hoad, Veronica C.
A1 Irving, David O.
A1 Dore, Gregory J.
A1 Gosbell, Iain B.
A1 Kelleher, Anthony D.
A1 Matthews, Gail V.
A1 Brilot, Fabienne
A1 Turville, Stuart G
YR 2021
UL http://medrxiv.org/content/early/2021/01/23/2020.12.19.20248567.abstract
AB The SARS-CoV-2 antibody neutralization response and its evasion by emerging viral variants are unknown. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 RT-PCR-confirmed COVID-19 individuals with detailed demographics and followed up to seven months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization were associated with COVID-19 severity. A subgroup of ‘high responders’ maintained high neutralizing responses over time, representing ideal convalescent plasma therapy donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal plasma donors and vaccine monitoring and design.One Sentence Summary Neutralizing antibody responses to SARS-CoV-2 are sustained, associated with COVID19 severity, and evaded by emerging viral variantsCompeting Interest StatementFB has received honoraria from Biogen Idec and Merck Serono as invited speaker. All other authors declare no competing interests.Funding StatementThis work was supported by Snow Medical (Australia), The University of New South Wales Rapid Response grant (Australia), the University of Sydney Research Excellence Initiative grant (Australia), and the MRRF NHRMC COVID-19 grant. The Australian Governments fund Australian Red Cross Lifeblood for the provision of blood, blood products, and services for the Australian community.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for this study was granted by St Vincents Hospital (2020/ETH00964) and Lifeblood (30042020) Research Ethics Committees. Written consent was obtained from all ADAPT patients. In LIFE, the donor consent form included a statement that blood donation may be used in research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCorrespondence and requests for data should be addressed to FB and may be limited due to ethical considerations. Plasmids transfer should be obtained through a MTA.